The $53.9 million capital infusion strengthens Ovid's cash position, potentially extending its runway for R&D; monitor for updates on clinical trial progress or future financing needs. While dilutive, the funding is a positive development for this small-cap biotech.
Price Chart
Executive Summary
Ovid Therapeutics Inc. announced that its Series A Warrants expired on April 17, 2026, resulting in the exercise of warrants into common stock and pre-funded warrants, generating approximately $53.9 million in gross proceeds for the company.
Key Facts
- Series A Warrants issued in October 2025 expired on April 17, 2026
- Investors exercised warrants into 33,597,860 shares of common stock at $1.40 per share
- 4,883,464 pre-funded warrants were exercised at $1.399 per share
- Total gross proceeds to the company amounted to approximately $53.9 million
Financial Impact
$53.9 million in gross proceeds from warrant exercises
Risk Factors
- Dilution from issuance of over 38 million new shares
- Future capital needs may require additional dilutive financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-025926 |
| Document: 0001628280-26-025926-index-headers.html | 0001628280-26-025926 |
| Document: 0001628280-26-025926-index.html | 0001628280-26-025926 |
| Document: 0001628280-26-025926.txt | 0001628280-26-025926 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 144 | $2.89 | awaiting T+60 | — | $2.26 (−21.80%) |
Jul 8, 2026 15w ago | 8-K | $2.73 $2.49 | ▼ −8.79% | ▼ −11.10% | $2.26 (−17.22%) |
Jun 3, 2026 20w ago | 8-K | $2.39 $2.93 | ▲ +22.59% | ▲ +20.10% | $2.26 (−5.44%) |
May 12, 2026 24w ago | Press Release | $2.87 $2.65 | ▼ −7.67% | ▼ −12.05% | $2.26 (−21.25%) |
Apr 27, 2026 26w ago | EFFECT | $2.69 $2.38 | ▼ −11.52% | ▼ −16.30% | $2.26 (−15.99%) |
Apr 21, 2026 27w ago | S-3 | $2.66 $2.44 | ▼ −8.27% | ▼ −13.05% | $2.26 (−15.04%) |
Apr 20, 2026 27w ago | 8-K | $2.89 $2.49 | ▼ −13.84% | ▼ −20.62% | $2.26 (−21.80%) |
Mar 18, 2026 31w ago | 8-K | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.26 (−1.74%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.26 (−1.74%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.26 (−1.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers